- Conditions
- Metastatic Malignant Neoplasm in the Brain, Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7
- Interventions
- 3-Dimensional Conformal Radiation Therapy, Erlotinib Hydrochloride, Stereotactic Radiosurgery, Temozolomide
- Radiation · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2012
- U.S. locations
- 80
- States / cities
- Scottsdale, Arizona • Burbank, California • Los Angeles, California + 67 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 101
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Glioblastoma, Glioblastoma Multiforme
- Interventions
- 5-day TMZ, 21-day TMZ, PEP-CMV: Component A, Tetanus-Diphtheria booster, Tetanus Pre-Conditioning, PEP-CMV: Component B
- Drug · Biological
- Lead sponsor
- Eric Thompson, M.D.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Carcinoma, Small Cell, Lung Cancer, Small Cell Lung Cancer
- Interventions
- M7824, Topotecan, Temozolomide, EKG, CT scan, PET scan, Acetaminophen, Antihistamines, Diphenhydramine, Dexamethasone, Epinephrine
- Drug · Diagnostic Test
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Glioblastoma Multiforme
- Interventions
- Temodar (Temozolomide), Hominex-2
- Drug · Dietary Supplement
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- Bortezomib, Temozolomide
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Ewing's Sarcoma
- Interventions
- Vigil, Temozolomide, Irinotecan, Gemcitabine, Docetaxel
- Biological · Drug
- Lead sponsor
- Gradalis, Inc.
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 6
- States / cities
- Little Rock, Arkansas • Miami, Florida • New York, New York + 2 more
- Conditions
- Colorectal Cancer
- Interventions
- Temozolomide + Olaparib
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Recurrent Adult Brain Neoplasm
- Interventions
- Laboratory Biomarker Analysis, Pharmacological Study, Temozolomide, Vorinostat
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2027
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 14 more
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- Concurrent temozolomide, Concurrent radiation therapy, 100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle, 75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle
- Drug · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 1,173 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2016
- U.S. locations
- 341
- States / cities
- Fairbanks, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 240 more
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- concomitant temozolomide (TMZ), radiotherapy, procarbazine, adjuvant temozolomide (TMZ), CCNU, vincristine
- Drug · Radiation
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 305 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2029
- U.S. locations
- 271
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 185 more
- Conditions
- Glioblastoma
- Interventions
- Intensity Modulated Radiation Therapy, Temozolomide, Functional Assessment of Cancer Therapy-Brain (FACT-Br), Stereotactic Radiosurgery Boost, Simultaneous Integrated Boost, 3D MRSI
- Radiation · Drug · Behavioral + 1 more
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- temozolomide
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2000
- U.S. locations
- 2
- States / cities
- Fort Sam Houston, Texas • San Antonio, Texas
- Conditions
- Brain Cancer, Glioblastoma Multiforme
- Interventions
- Vorinostat, Erlotinib, Temozolomide
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Relapsed Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
- Interventions
- Stenoparib/Temozolomide, Lurbinectedin
- Combination Product · Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 166 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 11
- States / cities
- Palo Alto, California • Chicago, Illinois • Indianapolis, Indiana + 8 more
- Conditions
- Lung Diseases, Cancer
- Interventions
- Combination Treatment - Cohort 1, Combination Treatment - Cohort 2, Combination Treatment - Cohort 3, Combination Treatment - Cohort 4
- Drug
- Lead sponsor
- New Mexico Cancer Research Alliance
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2011
- U.S. locations
- 1
- States / cities
- Albuquerque, New Mexico
- Conditions
- Non Small Cell Lung Cancer, CNS Progression
- Interventions
- Temozolomide plus Osimertinib, Temozolomide plus Lorlatinib
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Glioblastoma, Gliosarcoma
- Interventions
- Temodar, O6-BG, and Irinotecan
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Diffuse Intrinsic Pontine Glioma
- Interventions
- Bevacizumab, Erlotinib, Temozolomide, Radiation
- Drug · Radiation
- Lead sponsor
- Karen D. Wright MD
- Other
- Eligibility
- 3 Years to 18 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 20 more
- Conditions
- Ganglioneuroblastoma, Nodular, Neuroblastoma
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Dinutuximab, FDG-Positron Emission Tomography, Iobenguane I-123, Irinotecan, Isotretinoin, Magnetic Resonance Imaging, Multigated Acquisition Scan, Sargramostim, Temozolomide
- Procedure · Biological · Radiation + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 30 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 70
- States / cities
- Mesa, Arizona • Little Rock, Arkansas • Downey, California + 58 more
- Conditions
- Stage III Uterine Corpus Leiomyosarcoma AJCC v8, Stage IV Uterine Corpus Leiomyosarcoma AJCC v8, Uterine Corpus Leiomyosarcoma
- Interventions
- Computed Tomography, Core Biopsy, Magnetic Resonance Imaging, Olaparib, Temozolomide
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 15
- States / cities
- Phoenix, Arizona • Palo Alto, California • Aurora, Colorado + 11 more
- Conditions
- Anaplastic Astrocytoma, Glioblastoma
- Interventions
- trabedersen, temozolomide, Drug delivery system for administration of AP 12009, Placement of Drug Delivery System, carmustine, lomustine
- Drug · Device · Procedure
- Lead sponsor
- Isarna Therapeutics GmbH
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 3
- States / cities
- Edison, New Jersey • Mineola, New York • Rochester, New York
- Conditions
- Childhood Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Primary Central Nervous System Neoplasm, Refractory Malignant Solid Neoplasm, Refractory Primary Central Nervous System Neoplasm
- Interventions
- Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study, Sirolimus Albumin-bound Nanoparticles, Temozolomide
- Drug · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Los Angeles, California • Orange, California + 18 more
- Conditions
- Refractory Cancer, Refractory Neoplasm, Cancer Pediatric, Refractory Tumor, Pediatric Cancer, Pediatric Brain Tumor, Neuroblastoma, Neuroblastoma Recurrent, Pediatric Lymphoma, Pediatric Meningioma, Diffuse Intrinsic Pontine Glioma
- Interventions
- 9-ING-41, Irinotecan, Temozolomide, Cyclophosphamide, Topotecan
- Drug
- Lead sponsor
- Actuate Therapeutics Inc.
- Industry
- Eligibility
- Up to 22 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 9
- States / cities
- San Francisco, California • Aurora, Colorado • Chicago, Illinois + 6 more
- Conditions
- Solid Tumors, Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma, Hepatoblastoma, Medulloblastoma
- Interventions
- VAL-413, Temozolomide
- Drug
- Lead sponsor
- Valent Technologies, LLC
- Industry
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • San Francisco, California • Washington D.C., District of Columbia + 8 more